title: Evaluation of response to radiotherapy in head and neck cancer by positron emission tomography and [11C]methionine.
abstract: OBJECTIVE
  To evaluate the usefulness of positron emission tomography (PET) and L-[methyl-11C]methionine in assessing treatment response to radiotherapy in head and neck cancer.
  
  
  METHODS
  Fifteen patients with head and neck cancer (13 with squamous cell carcinoma, 1 with adenocystic carcinoma, and 1 with paranasal plasmocytoma) underwent a PET study with [11C]-methionine both before and after preoperative radiotherapy to the total tumor dose of 61-73 Gy. Twelve primary and 12 metastatic tumor sites were within the field of view. Nineteen of the 24 tumor sites were surgically explored after radiotherapy, and the tumor standardized uptake values (SUVs) of [11C]methionine were compared with histological findings.
  
  
  RESULTS
  All 24 malignant lesions were detectable in the pretreatment study. In all but one case, the tumor SUV decreased after radiotherapy. The median SUV of the tumor site was smaller (1.9, range, 1.3-3.1, n = 7) in cases with histologically verified complete response than in cases with persistent cancer (median 4.1, range, 2.8-7.6, n = 12, p = 0.0008). A complete histological response was verified in none of the 9 cases with a postirradiation SUV larger than the median (3.1), whereas 7 of the 10 cases with a SUV of 3.1 or smaller had complete response (p = 0.003). The preirradiation uptake of [11C]methionine in tumors did not have significant association with histological response (p = 0.45). The PET findings correlated well with follow-up data in five cases with unoperated tumor sites. The [11C]methionine uptake of the submandibular salivary glands decreased after radiotherapy (p = 0.04).
  
  
  CONCLUSIONS
  PET with [11C]methionine as a tracer may be useful in assessing response to radiotherapy in head and neck cancer. High uptake of [11C]methionine in the postirradiation scan suggests the presence of persistent disease.
authors.affiliation: Department of Oncology and Radiotherapy, Turku University Cyclotron/PET Center, Finland.
authors.forename: P
authors.initials: P
authors.lastname: Lindholm
authors.forename: S
authors.initials: S
authors.lastname: Leskinen-Kallio
authors.forename: R
authors.initials: R
authors.lastname: Grénman
authors.forename: P
authors.initials: P
authors.lastname: Lehikoinen
authors.forename: K
authors.initials: K
authors.lastname: Någren
authors.forename: M
authors.initials: M
authors.lastname: Teräs
authors.forename: U
authors.initials: U
authors.lastname: Ruotsalainen
authors.forename: H
authors.initials: H
authors.lastname: Joensuu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002250:Carbon Radioisotopes; D003528:Carcinoma, Adenoid Cystic / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D002294:Carcinoma, Squamous Cell / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D005260:Female; D006258:Head and Neck Neoplasms / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D006801:Humans; D008297:Male; D008715:Methionine; D008875:Middle Aged; D010954:Plasmacytoma / Q000000981:diagnostic imaging* / Q000532:radiotherapy; D014055:Tomography, Emission-Computed
chemical_list: D002250:Carbon Radioisotopes; D008715:Methionine